The first thing that we have to remember here is that this patient population is VERY sick. Unfortunately, the glioblastoma indication is one that is fatal more often than not. Moreover, fatality tends to happen quickly.
This is largely the result of inadequate treatment options. As mentioned earlier, the average survival rate is around 9.2 months in this patient population due to the few and largely ineffective options currently available.
With Diffusion Pharmaceuticals showing an increased survival rate already in the Phase 3 trial, it’s an understatement to say that this is a big deal. If all continues to go well, the safety and tolerability profile continues to be positive and median survival continues to climb, TSC or TSC in combination with the current standard of care, could quickly become the standard of care in this indication.
This could be massive for DFFN and its investors. After all, the glioblastoma market is expected to climb to be worth $1.4 billion annually by 2027. For a company with a market cap of just over $2 million, an opportunity to not only tap into, but take a large portion of a market this size is incredible, making this stock hard to ignore.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story
Join our free mailing list below to receive real-time news alerts!